Abivax closes $920 million ADS public offering

The biotech company said estimated net proceeds of about $874.1 million, combined with existing cash, should fund operations into the fourth quarter of 2029.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.